Lentiviral vectors for the preparation of immunotherapeutical compositions

US8349606B2 · kind B2 · utility

Assignees

• INSTITUT PASTEUR · FR
• Institut National de la Sante et de la Recherche Medicale (INSERM) · FR
• CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE · FR

Inventors

• Pierre Charneau · Paris, FR
• Hüseyin Firat · Paris, FR
• Veronique Zennou · Paris, FR

Key dates

• Filing date: May 10, 2011
• Grant date: Jan 8, 2013
• Expiry date: May 10, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2840/203
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to an immunogenic composition comprising a recombinant vector characterized in that it comprises a polynucleotide comprising the cis-acting central initiation region (cPPT) and the cis-acting termination region (CTS), these regions being of retroviral or retroviral-like origin, said vector comprising in addition a defined nucleotide sequence (transgene or sequence of interest) and regulatory signals of retrotranscription, expression and encapsidation of retroviral or retroviral-like origin, wherein the composition is capable of inducing or of stimulating a cell-mediated response for instance a CTL (Cytotoxic T Lymphocytes) response or a CD4 response, against one or several epitopes encoded by the transgene sequence present in the vector.